Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914086 | 0.72 | CYP2A6 (0.34) | ALDH1A1POLBCYP2A6 | |
| SCHEMBL2406497 | 0.72 | CYP2A6 (0.34) | ALDH1A1POLBCYP2A6 | |
| SCHEMBL28017359 | 0.66 | TSHR (0.42) | MAPTALDH1A1HPGDMEN1POLB | |
| SCHEMBL6198657 | 0.63 | ALDH1A1 (0.33) | MAPTALDH1A1HPGDMEN1POLB | |
| SCHEMBL27445737 | 0.62 | ALDH5A1 (0.53) | MAPTALDH1A1HPGDPDK1 | |
| SCHEMBL10937606 | 0.61 | PDK1 (0.50) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL9164494 | 0.59 | TSHR (0.38) | MAPTALDH1A1HPGDMEN1POLB | |
| SCHEMBL28132695 | 0.59 | TSHR (0.38) | MAPTALDH1A1HPGDMEN1POLB | |
| SCHEMBL14369940 | 0.58 | TSHR (0.52) | MAPTALDH1A1HPGDMEN1POLB | |
| SCHEMBL9004707 | 0.58 | FABP4 (0.45) | MAPTALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-02 | — | — | US | disclosed |
| EP-1409464-A1 | OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS | RANBAXY LABORATORIES, LTD. (IN) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003008389-A1 | OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242591-A1 | Oxazolidinone derivatives as pontential antimicrobials | PDK4, OXA1L, PPARD | MAPT 1094/4885ALDH1A1 1234/4885HPGD 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.